ASCO26: Sara Tolaney, MD, MPH, ASCENT-03 - Takeaways - MDSpire

ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.

  • July 1, 2026

Share

  • 1

    Dr. Sara Tolaney presented data from the ASCENT-03 study at ASCO26.

  • 2

    The study focuses on advanced triple-negative breast cancer.

  • 3

    Sacituzumab govitecan is being evaluated as a first-line treatment.

  • 4

    The data supports the case for its approval.

  • 5

    The research was conducted at Dana-Farber Cancer Institute.

Original Source(s)

ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

  • July 1, 2026

Related Content

RFX5 in cancer: context-dependent molecular functions and emerging translational relevance

Breast Cancer Incidence in Asian American, Native Hawaiian, and Pacific Islander Populations, 2000-2022

Hypoxia-driven tumor immune escape: mechanisms and therapeutic opportunities